The number of survivors having undergone high-dose therapy (HDT) followed by auto-SCT continues to increase, although some of the long-term sequelae remain incompletely understood. The immunological status and quality of life of 37 HDT/auto-SCT survivors with lymphoma in continuous remission of X3 years were assessed alongside 14 age-matched controls. At a median follow-up of 10.5 years (range 2.2-20.2) following HDT/auto-SCT, the proportion of CD4 þ cells remained significantly reduced in patients compared with controls (median 43.4% vs 62.5%, respectively; P ¼ o0.001), predominantly a result of sustained reduction in the naive CD4 þ component (Po0.001). Naive CD8 þ lymphocytes (P ¼ 0.014) and transitional B cells (P ¼ 0.008) were also significantly reduced, but differences in other lymphocyte subsets were not observed. Uptake of revaccination following HDT/auto-SCT was sporadic; between 11% and 33% of patients had serological titres outside the protective ranges for five of six routinely used vaccines. In the main, patients were found to have a good quality of life, although their EORTC QLQ-C30 questionnaire scores were significantly lower for the physical and social functioning domains compared with controls. Ten years after HDT/auto-SCT immunological deficits persist; to avoid excess risk of preventable disease, serological immunity should be assessed post HDT/ auto-SCT followed by appropriate revaccination.
INTRODUCTION
High-dose therapy (HDT) followed by auto-SCT has become well recognised as an effective therapy in the treatment of relapsing patients with Hodgkin's disease and a variety of non-Hodgkin's lymphoma. [1] [2] [3] [4] However, as the number of survivors who have undergone HDT steadily increases, there are unanswered questions arise regarding the long-term sequelae of this approach. Although much data have been published on efficacy outcomes such as PFS and OS following auto-SCT, there are only a few studies on long-term physical health, quality of life and immunological function for these patients. Although it is understood that haematopoietic transplantation is associated with a profound immune deficiency, prior research into immune reconstitution following the procedure has focused largely on allogeneic transplantation recipients. Immunological studies that have investigated auto-SCT have recruited small numbers of patients over a relatively short time frame, with the interpretation confounded by purging or selection techniques, which are now less commonly employed. [5] [6] [7] Existing research has shown that deficits in cellular and humoral immunity may persist for many years post transplant 7, 8 and that serological memory of primary vaccination may be compromised post HDT/auto-SCT. [9] [10] [11] In response to concerns over the loss of specific immunity, recommendations for a full revaccination programme following both allogeneic and autologous transplants have been published by the Centre for Disease Control 12 as well as the European Group for Blood and Marrow Transplantation and the American Society of Blood and Marrow Transplantation. 13, 14 However, routine revaccination of patients after auto-SCT has not been aggressively pursued or monitored in many centres, which may render many such patients at an excess risk of preventable disease.
The aims of this research were to investigate the long-term immunological status of patients treated with HDT/auto-SCT for malignant lymphoma. Data on the phenotypic profile of peripheral blood-derived lymphocyte subsets, including more recently recognised populations, as well as serological memory of primary vaccination were gathered from patients in continuous remission of at least 3 years following HDT. Quantitative assessment of long-term quality of life was also performed. The purpose of this study was to better inform the long-term follow-up of these patients and provide evidence for the potential benefit of a revaccination programme after HDT.
Healthy volunteers were recruited to the study to serve as a control population. Volunteers were largely drawn from partners and relatives accompanying patient participants, were age matched to the patient population and had no history of neoplastic disease. This study had full Research Ethics Committee approval and all participants were required to provide written informed consent before enrolment in the study.
Study procedures
Before each consultation, a retrospective notes review was performed to gather information on patient demographics, diagnosis, previous treatments and transplantation details. At the study visit, patients were asked to supply a record of immunisations received before and after HDT to enable an accurate vaccination history to be recorded for each patient. Patients who were unable to provide a pre-transplant vaccination history were assumed to have received immunisations consistent with the timeline of vaccine introduction in the UK and their date of birth. Both patient and control subjects were asked to complete a psychometrically robust quality of life questionnaire: the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 version 3. 15 The QLQ-C30 is a 30-item assessment tool that has been commonly used in research into quality of life among cancer patients and extensively evaluated in its practicality, reliability and validity. 16 A single venesection was then performed to collect peripheral blood for the laboratory procedures outlined below.
Storage of PBMCs
PBMCs were isolated and frozen from EDTA tubes in line with the standard operating procedure. Briefly, this involved mixing the anti-coagulated blood with an equal quantity of complete cRPMI. This solution was then carefully overlain onto 12 mL of Ficoll-Paque (GE Biosciences, Chalfont, UK) and centrifuged. The PBMC containing interface layer was then removed, made up with cRPMI and centrifuged. The cells were resuspended in 1 mL of freezing medium consisting of 40% cRPMI, 50% human AB serum and 10% DMSO. Samples were frozen at 5-10 Â 10 6 /mL in individual cryovials at À 80 1C overnight using an isopropanol nalgene box and then transferred to liquid nitrogen storage tanks.
Enumeration of PBMC subtypes
Frozen PBMCs were rapidly thawed in a 37-1C water bath, washed twice in PBS, then stained with calcein acetoxymethyl ester supplied in the Live/ Dead Violet Viability/Vitality Kit (Invitrogen, Paisley, UK) according to the manufacturer's instructions. Up to 1.0E6 cells were stained in 100 mL of the below antibody combinations in PBS, 0.5% BSA, 0.01% sodium azide and 10% human AB serum in V-bottomed plates on ice for 25 min, then washed twice in the same solution. Flow cytometric analysis was performed using a BD FACS Canto II with three lasers and BD FACSDiva software (version 6.1.2, BD Biosciences, Franklin Lakes, NJ, USA).
T-cell, B-cell and NK-cell (TBNK) antibody panel-antigens: CD3, CD16, CD56, CD45, CD4, CD19 and CD8. T-cell antibody panel-antigens: CD45RA, CCR4, CD3, CCR7, CD183 and CD4. B-cell antibody panelantigens: IgD, CD27, CD21, CD10, CD38, CD19 (all antibodies from BD Biosciences). FACS panels were constructed to identify cell lineages as shown in Figure 1 .
Immunovirological assessments
Quantification of serum IgG antibody levels against measles, mumps, rubella, Haemophilus influenzae type B (HiB), tetanus and pneumococcus were performed using commercially available ELISA methodologies through the Clinical Immunology and Public Health Laboratory Services. Normal ranges to denote immunity were established from the Finish Public Health Service and predetermined values within the Southampton University Hospitals Trust.
Statistics
Analysis of cell subset data derived from flow cytometry was performed using the non-parametric Mann-Whitney U test in Prism GraphPad (version 4.03). Trends relating to time or age were graphically produced in Microsoft Excel (2003 edition) using standardized correlation coefficients. Data from the EORTC QLQ-C30 were transformed into subscales and analysed according to the instruments scoring guidelines. 17 Findings where P was o0.05 were considered significant.
RESULTS
A total of 130 suitable patients in continuous remission for at least 3 years were identified from the transplant database and invited to participate. From the positive responders, 37 patients and 14 healthy volunteers consented to study inclusion. Two patients were included who were of 26 and 34 months remission at the point of enrolment, producing a median time since transplant of 10.5 years (range 2.2-20.0 years). The median age of the patient and control populations were 52 years (range 30-71) and 56 years (range 44-76), respectively. Full demographics are presented in Table 1 . No secondary malignancies were recorded among the volunteer patient population.
Lymphocyte subsets
The overall proportions of T, B and NK cells were broadly akin between patients and healthy volunteers (Table 2) . Similarly, no significant differences were observed in the proportions of CD56 bright NK cells, T natural killer cells (TNK) or double-negative (DN) T cells.
Within the T-cell population, marked differences were seen in the ratios of CD4 þ /CD8 þ T cells, with a significantly lower proportion of CD4 þ cells in patients compared with controls (Po0.001). Further analysis of CD4 þ compartments demonstrated a preponderance of memory CD4 þ cells with a profound reduction in the proportion of naive CD4 þ cells in the patient population (Po0.001). CD4 þ memory subtypes also showed highly significant variation between patients and controls, with a raised proportion of effector and central memory CD4
þ cells among the patient group. Among patients, the proportion of CD4 þ cells appeared to increase with time from transplantation ( Figure 2 ), but decrease with patient's age. No correlation was observed between these variables and the proportion of naive CD4 þ cells. A reduced proportion of naive T cells was also seen within the CD8 þ population, together with a corresponding increase in the level of memory CD8 þ cells (P ¼ 0.014). Unlike the CD4 þ population, however, no significant differences were observed in the level of central or effector memory CD8 þ cells between the patient and control groups.
Enumeration of B-cell subsets produced similar findings in both patients and healthy volunteers, with no statistically significant differences discernable in the proportion of memory or naive cells. Likewise, no difference was seen in the percentages of mature plasmablasts, marginal zone-like or class switch cells. The mean percentage of transitional B cells, however, was found to be reduced in patients as compared with controls (P ¼ 0.008).
Vaccination history and serological memory Vaccination among patients following HDT was fairly sporadic and in most cases was related to travel abroad or opportunistic Defects in lymphocyte subsets and serological memory HF Dean et al administration by general practitioners. Though a proportion of patients had been vaccinated to tetanus (41%), pneumococcus (35%), polio (27%), diphtheria (22%) and typhoid (14%) since HDT, only 5% had received repeated vaccination dosages and only one patient had completed a full three-step primary revaccination. None of the patients seen in this study had received vaccinations for pertussis, measles, mumps or rubella following transplantation, while only one patient had been vaccinated against HiB since auto-SCT. Forty-six per cent of patients had received the H 1 N 1 swine flu vaccine following auto-SCT, with the same number also receiving a regular seasonal flu vaccine. Two patients reported a case of mumps following auto-SCT.
Mean concentrations of serum antibody were higher among patients who had been vaccinated at any point following HDT as compared with those who did not encounter revaccination (Figure 3) . Three patients possessed titres on the borderline of minimum protective level for tetanus immunity, one of whom had received a single-dose vaccine. One-third of the patients tested lacked sufficient immunity to pneumococcus. Eleven per cent of the patients were below the minimum and 64% below the optimal protective levels for HiB immunity. Eighteen per cent of the female patients possessed sub-protective titres for rubella. The percentage of patients below the minimum titre level for measles and mumps was 17% and 25%, respectively. No correlation was found between levels of immunity and time from transplant for any of the pathogens.
Quality of life assessment
Results from analysis of the EORTC QLQ C-30 domains showed a lower mean score for patients than for controls across all scales (Figure 4 ), but were only significant for physical (patients 96.66 vs control 87.02; P ¼ 0.009) and social functioning domains (patients 98.80 vs control 87.38; P ¼ 0.032). Analysis of symptom scores revealed increased symptomatology among the patient group for a variety of different physical and executive items ( Figure 5 ). Of these, significant differences were only seen for dyspnoea (patient 9.0 vs control 0.0; P ¼ 0.010) and financial difficulties (patient 8.10 vs control 0.0; P ¼ 0.003).
DISCUSSION
This study represents one of the most comprehensive assessments of long-term survivors of HDT/auto-SCT to date. In general, most patients were doing well and very few had serious health concerns. Immunologically, however, it is clear that at a median of 10 years follow-up a sizeable proportion of patients continue to harbour significant abnormalities in the composition and protective status of their immune system. In comparison to previously published research, our study was able to enrol a relatively large number of patients despite a response rate of only 30% from the potential 130 patients. It is possible, however, that positive responders may have been in better health at the point of invitation and the authors acknowledge the potential impact of such a selection bias. This may additionally explain why no secondary malignancies were observed within the patient population.
The results of this investigation demonstrate a persistent reduction in the proportion of CD4 þ T cells and deranged CD4 þ /CD8 þ ratios for many years post transplant. Although these observations concur with shorter-term studies by Pedrazzini 7 and Nørdoy, 8 the imbalances observed in our patients as much as 20 years after HDT imply that this feature may continue to be redressed over a much larger time frame than first thought. In particular, the proportion of naive CD4 þ and CD8 þ cells was markedly reduced in survivors when compared with healthy volunteers. This has the potential to produce a peripheral T-cell compartment with a restricted TCR repertoire and an impaired ability to respond to novel antigenic challenges not previously encountered by the patient, as well as pathogens for which specific memory cells have not been re-established from the graft. These defects reveal that the ability of the thymus to produce new naive helper and cytotoxic cells is compromised following HDT. Furthermore, the enlarged memory T-cell population might represent proliferation of a limited number of clones through homeostatic peripheral expansion and thymicindependent pathways. This theory is supported by Heitger et al., 18 who describe that, although a thymus-independent pathway exists to regenerate CD45RA þ CD8 þ cells, residual thymus is essential for the reconstitution of naive CD45RA þ CD4 þ cells after haematopoietic transplantation. In a study of autologous transplant patients with multiple myeloma, Douek et al. 19 measured levels of recent thymic emigrants using analysis of T-cell receptor rearrangement excision circles. They reported that increased thymic output correlated with and was predictive of increased naive T-cell numbers and broader T-cell repertoires.
Other researchers have published that the reduction in naive CD4 cells after allogeneic transplantation is unrelated to thymic output, but is instead linked to impaired naive T-cell survival resulting from reduced expression of IL-7 receptor a and antiapoptotic Bcl-2. 20 The presence of similarly altered cell signalling pathways in CD8 þ cell populations may also help to explain the reduction in naive CD8 þ cells observed in the present study group.
There are few data available on the effect of age on the pattern of CD4 þ reconstitution after HDT and it is therefore difficult to assess the impact of age-related thymic involution on this group of patients. Given the age-matched control group used in this study together with the poor correlation between age and naive or total CD4 þ cells, it appears that HDT and autologous transplantation exerts a profound and enduring effect on T-cell production independent of the patient's age. Further research is required to fully elucidate the exact role of the thymus in immune reconstitution following auto-SCT to direct opportunities for immunotherapy. The development of interventions capable of boosting thymic output such as recombinant human IL-7 21 or sex steroid ablation could help to attenuate the T-cell immunodeficiency associated with HDT and improve immune recovery.
The analysis of further T-cell subsets in this patient population was not revealing of any additional specific immunological malfunction. A similar increase in the relative proportions of effector and central memory CD4
þ cells among patients is most likely indicative of the reduced proportion of naive CD4
þ cells rather than a congruent increase in each of the memory populations, particularly as the levels of effector memory RA were normal.
Analysis of B-cell subsets showed a great deal of similarity between the two study groups, showing that by 2-3 years post transplant the majority of patients have recovered normal B-cell ratios and phenotypically at least; this is consistent with the completion of B-cell reconstitution. The one exception to this was the transitional B-cell population, which paradoxically was significantly lower in patients than in controls (P ¼ 0.008), for which there is currently no explanation. As with the T-cell measurements performed in this study, it is worth noting, however, that normal circulating percentages or a normal subset composition does not necessarily imply a lack of functional defects.
Revaccination following HDT among this group of patients was generally poor. The majority of patients were inadequately informed about vaccination, resulting in one patient receiving a potentially hazardous live vaccine (yellow fever) and several patients unnecessarily avoiding beneficial immunisations through misconceptions over their safety.
Lack of sufficiently protective immunity was common and a significant proportion of patients were observed to be at a heightened risk of infection for five out of six of the pathogens tested in this analysis. The observation that several patients who had received one-off vaccinations after HDT failed to mount a sufficient immune response to confer protective immunity validates the report by Ljungman et al., 14 recommending complete primary revaccination utilising a schedule of repeated doses.
The lack of comparative values before HDT means it is not possible to definitively conclude whether or not these findings are directly attributable to HDT/auto-SCT. Added to this, vaccines for several of the pathogens tested in this study were not nationally introduced until the 1960s and were therefore unavailable to the older participants of this study. Consequently, we found that a large proportion of patients had not been vaccinated against several of the pathogens before HDT (measles 81% unvaccinated, mumps 95% and pneumococcus 96%) and so broad comparisons about changes in the percentage of immune patients before HDT and at follow-up may be misleading. This notwithstanding, the data from this study provide a sagacious rationale for assessment of serological titres after HDT followed by appropriately structured and consistent revaccination as a matter of routine.
The fact that two cases of mumps were reported at interview further demonstrate the potential to protect these patients from a recognisable burden of infectious disease. Although long-term prospective trials are required to conclusively demonstrate the benefit of revaccination and its cost-effectiveness, the scarcity of adverse events, low set-up cost and minor logistical barriers involved in complying with a revaccination programme mean there is a limited case against its implementation.
Data on long-term quality of life and psychosocial recovery after auto-SCT are relatively limited and little research has been performed beyond the first year after transplant. From the quantitative patient responses in this study, it can be seen that most patients on the whole enjoy a good quality of life. Our analysis did, however, detect a lower average score (and therefore quality of life) among patients compared with control across all scales, even at a median of 10 years after HDT. Our study adds further support to existing evidence that the process of psychological and emotional recovery extends well beyond the period of physical recuperation, and complete recovery after haematopoietic transplant may take many years. 22 In summary, the results of this study demonstrate persistent immunological abnormalities in patients at a median follow-up of 10 years, including deranged CD4 þ /CD8 þ ratios and reduced percentages of naive CD4 þ T lymphocytes. A large proportion of patients are inadequately protected against vaccinatable infectious agents and failing to implement strategies for comprehensive revaccination following auto-SCT may place these patients at an excess risk of preventable disease. Although most patients are doing well, some continue to experience a reduced quality of life related to impaired physical and social functioning for an indefinite period of time following haematopoietic transplant. Clinicians must be aware of a host of factors that may affect the patient's health and wellbeing in order to provide the best possible follow-up care.
